Abstract 8000: Polygenic Risk Identifies Early-Life LDL-C Elevation and Highlights Treatment Opportunities in a U.S. Clinical Population
Abstract
Introduction: Hypercholesterolemia (HC) is a major driver of cumulative atherosclerotic cardiovascular disease (ASCVD) risk across the lifespan. While polygenic risk scores (PRS) for HC may complement monogenic familial hypercholesterolemia (FH) testing, their relationship to early-life LDL-C burden and clinical management remains unclear. Methods: We analyzed genetic and electronic health record data from 19,602 adult (18-75 yrs, mean 50.6) and 4,251 pediatric (3-17 years, mean 11.7) participants enrolled across 10 U.S. clinical sites in the Electronic Medical Records and Genomics IV study. Adults were classified as monogenic FH (FH+; n=139; 0.7%), high (top 3%) PRS (PRS+; n=412; 2.1%), or “not-high-risk” (NHR; n=19,051; 97.2%). The same PRS were calculated in children (n=81 with high HC PRS; children did not have monogenic testing). We performed replication analyses in an age-matched cohort from the All of Us Research Program v8 (AoU; n=361,475; 2.2% PRS+). Results: We observed higher LDL-C levels in the PRS+ group vs. the NHR group beginning in childhood (mean 104 vs 89 mg/dL; p=0.004), peaking between ages 26-35 (137 vs 102 mg/dL; p=1x10-12), and persisting throughout adulthood until age 65. For comparison, FH+ was also associated with higher LDL-C in early life (e.g. 26-35 yrs: 149 mg/dL). PRS+ had higher rates of lipid disorder diagnoses across all age bins (overall rate ratio: 1.4; p=1x10-30) but no significant increase in lipid-lowering therapy prescriptions until ages 36-45. In contrast, FH+ were 5.5 times more likely to have a prescription by ages 26-35 (p=5x10-10). Among all 4,250 treated adults, PRS+ were 42% less likely and FH+ were 70% less likely to achieve LDL-C under 100 mg/dL (p=0.003 and p=9x10-5, respectively) vs. the NHR group. Findings replicated independently in AoU, where PRS+ had higher LDL-C (e.g. 26-35 yrs: 119 vs 100 mg/dL), increased HC diagnosis rates, delayed lipid-lowering therapy initiation, and were 23% less likely to achieve LDL-C under 100 mg/dL when treated (p=6x10-9). Conclusions: Our findings reveal elevated LDL-C since childhood and a potential systematic delay of treatment for PRS-defined HC risk compared to FH across the life course. This highlights an opportunity to identify high-risk individuals earlier and implement more timely lipid-lowering interventions to reduce ASCVD burden through the integration of HC PRS in clinical practice.